
|Videos|October 18, 2017
Dr. Zandberg on Biomarker Development in Head and Neck Cancer
Author(s)Dan Zandberg, MD
Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.
Advertisement
Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.
Biomarkers are important for determining which immunotherapy regimen a patient should receive, says Zandberg. Currently, in head and neck cancer there has not been an identified biomarker to predict response to these therapies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 1/25
2
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5



































